A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly)
Adam de Belder, Jose M de la Torre Hernandez, Ramon Lopez-Palop, Peter O'Kane, Felipe Hernandez Hernandez, Julian Strange, Federico Gimeno, James Cotton, Jose F Diaz Fernandez, Pilar Carrillo Saez, Martyn Thomas, Eduardo Pinar, Nick Curzen, Jose A Baz, Nina Cooter, Inigo Lozano, Nicola Skipper, Derek Robinson, David Hildick-Smith, XIMA Investigators, Adam de Belder, Jose M de la Torre Hernandez, Ramon Lopez-Palop, Peter O'Kane, Felipe Hernandez Hernandez, Julian Strange, Federico Gimeno, James Cotton, Jose F Diaz Fernandez, Pilar Carrillo Saez, Martyn Thomas, Eduardo Pinar, Nick Curzen, Jose A Baz, Nina Cooter, Inigo Lozano, Nicola Skipper, Derek Robinson, David Hildick-Smith, XIMA Investigators
Abstract
Objectives: The aim of this study was to determine whether drug-eluting stents (DES) are superior to bare-metal stents (BMS) in octogenarian patients with angina.
Background: Patients ≥80 years of age frequently have complex coronary disease warranting DES but have a higher risk of bleeding from prolonged dual antiplatelet therapy.
Methods: This multicenter randomized trial was conducted in 22 centers in the United Kingdom and Spain. Patients ≥80 years of age underwent stent placement for angina. The primary endpoint was a 1-year composite of death, myocardial infarction, cerebrovascular accident, target vessel revascularization, or major hemorrhage.
Results: In total, 800 patients (83.5 ± 3.2 years of age) were randomized to BMS (n = 401) or DES (n = 399) for treatment of stable angina (32%) or acute coronary syndrome (68%). Procedural success did not differ between groups (97.7% for BMS vs. 95.4% for DES; p = 0.07). Thirty-eight percent of patients had ≥2-vessel percutaneous coronary intervention, and 66% underwent complete revascularization. Patients who received BMS had shorter stent implants (24.0 ± 13.4 mm vs. 26.6 ± 14.3 mm; p = 0.01). Rates of dual antiplatelet therapy at 1 year were 32.2% for patients in the BMS group and 94.0% for patients in the DES group. The primary endpoint occurred in 18.7% of patients in the BMS group versus 14.3% of patients in the DES group (p = 0.09). There was no difference in death (7.2% vs. 8.5%; p = 0.50), major hemorrhage (1.7% vs. 2.3%; p = 0.61), or cerebrovascular accident (1.2% vs. 1.5%; p = 0.77). Myocardial infarction (8.7% vs. 4.3%; p = 0.01) and target vessel revascularization (7.0% vs. 2.0%; p = 0.001) occurred more often in patients in the BMS group.
Conclusions: BMS and DES offer good clinical outcomes in this age group. DES were associated with a lower incidence of myocardial infarction and target vessel revascularization without increased incidence of major hemorrhage. (Xience or Vision Stent-Management of Angina in the Elderly [XIMA]; ISRCTN92243650).
Keywords: bare-metal stent(s); drug-eluting stent(s); octogenarians.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed